Search

Emergent BioSolutions Inc

Закрыт

СекторЗдравоохранение

6.2

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

6.15

Макс.

6.28

Ключевые показатели

By Trading Economics

Доход

-187M

-180M

Продажи

78M

234M

P/E

Средняя по отрасли

8.634

56.659

Прибыль на акцию

0.6

Рентабельность продаж

-76.91

Сотрудники

900

EBITDA

-205M

-156M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+60.51% upside

Дивиденды

By Acuity

Следующий отчет о доходах

28 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-74M

303M

Предыдущая цена открытия

6.2

Предыдущая цена закрытия

6.2

Новостные настроения

By Acuity

42%

58%

125 / 339 Рейтинг в Healthcare

Emergent BioSolutions Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 сент. 2026 г., 20:03 UTC

News

Emergent BioSolutions faces investigation amid $191.3 million impairment charge and $180.2 million net loss, contributing to shares trading lower today.

2 сент. 2026 г., 19:53 UTC

News

Emergent BioSolutions Inc. is under investigation related to recent financial disclosures, following a significant net loss and reduced revenue guidance. Shares are higher today.

1 сент. 2026 г., 20:09 UTC

News

Emergent BioSolutions secures a $24 million contract modification from BARDA for its anthrax vaccine, CYFENDUS®, as shares rise in Tuesday trading.

31 авг. 2026 г., 20:02 UTC

News

Emergent BioSolutions secures a Canadian government contract for NARCAN® Nasal Spray, boosting shares during Monday's session. The agreement runs from October 2026 to September 2029.

28 авг. 2026 г., 20:07 UTC

News

Emergent BioSolutions shares are lower amid an investigation by Bronstein, Gewirtz & Grossman, LLC, following a $191.3 million impairment charge and reduced revenue guidance.

27 авг. 2026 г., 20:07 UTC

News

Emergent BioSolutions Inc. is under investigation, following a $180.2 million net loss and reduced revenue guidance, contributing to a decline in shares today.

26 авг. 2026 г., 20:08 UTC

Emergent BioSolutions Inc shares are higher, reflecting strong upward momentum since Tuesday. The stock remains well above its 20-day moving average.

25 авг. 2026 г., 20:07 UTC

Emergent BioSolutions Inc shares are higher during Tuesday's session, continuing a strong advance since Monday's close amid easing Treasury yields and lower oil prices.

24 авг. 2026 г., 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a cumulative increase since Friday. The stock remains below its 20-day moving average.

21 авг. 2026 г., 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a steady upward trend since Thursday's close. No specific news was identified to explain the movement.

20 авг. 2026 г., 19:02 UTC

News

Emergent BioSolutions Inc faces scrutiny after a $191.3 million impairment charge and a reduced revenue outlook, contributing to a decline in shares.

19 авг. 2026 г., 19:52 UTC

Emergent BioSolutions Inc is trading higher during Wednesday's session, recovering from earlier lows and reflecting strength since Tuesday's close. No specific news was identified.

18 авг. 2026 г., 20:06 UTC

Emergent BioSolutions Inc shares are higher today, reflecting a broader market recovery. The stock remains below its 20-day moving average and prior month levels.

17 авг. 2026 г., 19:56 UTC

News

Emergent BioSolutions faces investigations over financial disclosures, including a $191.3 million impairment charge, contributing to lower shares amid declining investor confidence.

13 авг. 2026 г., 19:51 UTC

Macro Event

Emergent BioSolutions Inc shares are roughly flat as jobless claims rise to 209,000, exceeding expectations. The stock remains below its 20-day moving average.

12 авг. 2026 г., 19:26 UTC

Emergent BioSolutions Inc gains amid broader market optimism following inflation data. The stock reached a session high before slightly pulling back.

11 авг. 2026 г., 22:56 UTC

Emergent BioSolutions Inc shares are trading lower in after-market hours. No specific news was identified to explain the movement.

10 авг. 2026 г., 19:51 UTC

News

Emergent BioSolutions shares are trading lower as H.C. Wainwright reduced its price target to $10.00, citing concerns over performance and outlook amid competitive pressures.

7 авг. 2026 г., 23:26 UTC

Emergent BioSolutions Inc shares rose in after-market trading, amid positive market sentiment and notable gains in major tech stocks. No specific news was identified.

6 авг. 2026 г., 23:41 UTC

Emergent BioSolutions traded roughly flat after market hours, with no specific news identified. The stock has declined significantly over the past month.

5 авг. 2026 г., 22:51 UTC

News

Emergent BioSolutions shares are lower in after-market hours following a Q2 net loss of $180.2 million and reduced full-year sales guidance.

29 июл. 2026 г., 19:56 UTC

Emergent BioSolutions Inc shares are trading higher Wednesday, reflecting gains since Tuesday's close, despite earlier fluctuations and broader market pressures.

27 июл. 2026 г., 18:46 UTC

Emergent BioSolutions Inc shares are higher amid a broader market trend, despite pulling back from earlier session highs. Crude oil prices have significantly declined.

23 июл. 2026 г., 19:36 UTC

Emergent BioSolutions Inc shares are lower, reflecting broader market trends amid negative earnings from major technology companies like Tesla and Alphabet.

Сравнение c конкурентами

Изменение цены

Emergent BioSolutions Inc Прогноз

Целевая цена

By TipRanks

60.51% рост

Прогноз на 12 месяцев

Средняя 10 USD  60.51%

Максимум 10 USD

Минимум 10 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Emergent BioSolutions Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

2 ratings

1

Покупка

0

Удержание

1

Продажа

Настроения

By Acuity

125 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat